SG47786A1 - Method of treating crohn's disease ulcerative colitis or ulcerative proctitis - Google Patents

Method of treating crohn's disease ulcerative colitis or ulcerative proctitis

Info

Publication number
SG47786A1
SG47786A1 SG1996004367A SG1996004367A SG47786A1 SG 47786 A1 SG47786 A1 SG 47786A1 SG 1996004367 A SG1996004367 A SG 1996004367A SG 1996004367 A SG1996004367 A SG 1996004367A SG 47786 A1 SG47786 A1 SG 47786A1
Authority
SG
Singapore
Prior art keywords
ulcerative
disease
proctitis
treating crohn
ulcerative colitis
Prior art date
Application number
SG1996004367A
Other languages
English (en)
Inventor
Craig Eugene Caufield
John Henry Musser
Surendra Nath Sehgal
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SG47786A1 publication Critical patent/SG47786A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG1996004367A 1992-08-17 1993-08-06 Method of treating crohn's disease ulcerative colitis or ulcerative proctitis SG47786A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/931,243 US5286731A (en) 1991-09-17 1992-08-17 Method of treating immunoinflammatory bowel disease

Publications (1)

Publication Number Publication Date
SG47786A1 true SG47786A1 (en) 1998-04-17

Family

ID=25460461

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996004367A SG47786A1 (en) 1992-08-17 1993-08-06 Method of treating crohn's disease ulcerative colitis or ulcerative proctitis

Country Status (13)

Country Link
US (1) US5286731A (de)
EP (1) EP0583925B1 (de)
JP (1) JP2637682B2 (de)
KR (1) KR100299395B1 (de)
AT (1) ATE166786T1 (de)
AU (1) AU677011B2 (de)
CA (1) CA2104042A1 (de)
DE (1) DE69318902T2 (de)
DK (1) DK0583925T3 (de)
ES (1) ES2116415T3 (de)
GR (1) GR3027610T3 (de)
HK (1) HK1009641A1 (de)
SG (1) SG47786A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US6204243B1 (en) 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
NZ333657A (en) 1996-07-30 2000-05-26 Novartis Ag A pharmaceutical composition comprising cyclosporin A and 40-O-(2-hydroxyethyl)-rapamycin
IT1289815B1 (it) * 1996-12-30 1998-10-16 Sorin Biomedica Cardio Spa Stent per angioplastica e relativo procedimento di produzione
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
DK1319008T3 (da) 2000-09-19 2009-02-09 Wyeth Corp Vandoplöselige rapamycinestere
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
US20040018228A1 (en) * 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
EP1392321B1 (de) * 2001-03-15 2010-08-18 Soligenix, Inc. Verfahren zur behandlung von entzündlichen erkrankungen des verdauungstrakts mit topisch wirksamen kortikosteroiden
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
MXPA04001524A (es) 2001-08-22 2004-05-31 Wyeth Corp 29-enoles de rapamicina.
CA2455311A1 (en) 2001-08-22 2003-03-06 Wyeth Rapamycin dialdehydes
US20040137066A1 (en) * 2001-11-26 2004-07-15 Swaminathan Jayaraman Rationally designed therapeutic intravascular implant coating
US6641611B2 (en) 2001-11-26 2003-11-04 Swaminathan Jayaraman Therapeutic coating for an intravascular implant
EA008379B1 (ru) 2002-02-01 2007-04-27 Ариад Джин Терапьютикс, Инк. Фосфорсодержащие соединения и их применения
ATE385795T1 (de) 2002-07-30 2008-03-15 Wyeth Corp Parenterale formulierungen mit einem rapamycin hydroxyester
US20040077677A1 (en) * 2002-09-17 2004-04-22 Wyeth Oral formulations
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
DK1615640T3 (da) * 2003-04-22 2007-03-12 Wyeth Corp Antineoplastiske sammensætninger
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US7151085B2 (en) * 2004-11-15 2006-12-19 Allergan, Inc. Therapeutic methods using cyclosporine components
US7135455B2 (en) * 2004-11-15 2006-11-14 Allergan, Inc Methods for the therapeutic use of cyclosporine components
JP5709354B2 (ja) 2005-11-14 2015-04-30 アリアド・ファーマシューティカルズ・インコーポレイテッド ｍＴＯＲ阻害剤投与によるがん患者の治療
RU2010104916A (ru) * 2006-08-16 2011-08-20 Михаил В. Благосклонный (US) Способ профилактики и лечения возрастных заболеваний
WO2008033956A2 (en) 2006-09-13 2008-03-20 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
JP2012504654A (ja) * 2008-10-03 2012-02-23 エリクシアー メディカル コーポレイション 多環状ラクトン化合物およびその使用方法
US20120064143A1 (en) 2008-11-11 2012-03-15 The Board Of Regents Of The University Of Texas System Inhibition of mammalian target of rapamycin
KR20130128018A (ko) * 2009-04-10 2013-11-25 하이얀 치 새로운 노화 방지 물질 및 그 확인 방법
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US20110150856A1 (en) * 2009-12-21 2011-06-23 Sarah Bacus Compositions and methods for treatment of vitiligo
US20160030401A1 (en) 2013-03-13 2016-02-04 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) * 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
GB2212061B (en) * 1987-11-09 1991-08-28 Sandoz Ltd Topical compositions comprising 11,28-dioxa-4-azatricyclo [22.3.1.0(4,9)] octacos-18-ene derivatives
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5023264A (en) * 1990-07-16 1991-06-11 American Home Products Corporation Rapamycin oximes
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
ES2118087T3 (es) * 1990-08-10 1998-09-16 Anormed Inc Composiciones inmunosupresoras.
US5078999A (en) * 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5080899A (en) * 1991-02-22 1992-01-14 American Home Products Corporation Method of treating pulmonary inflammation
US5091389A (en) * 1991-04-23 1992-02-25 Merck & Co., Inc. Lipophilic macrolide useful as an immunosuppressant
US5138051A (en) * 1991-08-07 1992-08-11 American Home Products Corporation Rapamycin analogs as immunosuppressants and antifungals
US5102876A (en) * 1991-05-07 1992-04-07 American Home Products Corporation Reduction products of rapamycin
US5286730A (en) * 1991-09-17 1994-02-15 American Home Products Corporation Method of treating immunoinflammatory disease

Also Published As

Publication number Publication date
DE69318902D1 (de) 1998-07-09
ATE166786T1 (de) 1998-06-15
ES2116415T3 (es) 1998-07-16
JPH06183967A (ja) 1994-07-05
DE69318902T2 (de) 1999-02-25
EP0583925B1 (de) 1998-06-03
AU4465493A (en) 1994-02-24
GR3027610T3 (en) 1998-11-30
HK1009641A1 (en) 1999-06-04
CA2104042A1 (en) 1994-02-18
AU677011B2 (en) 1997-04-10
EP0583925A1 (de) 1994-02-23
DK0583925T3 (da) 1998-10-12
KR940003555A (ko) 1994-03-12
US5286731A (en) 1994-02-15
KR100299395B1 (ko) 2001-10-22
JP2637682B2 (ja) 1997-08-06

Similar Documents

Publication Publication Date Title
SG47786A1 (en) Method of treating crohn's disease ulcerative colitis or ulcerative proctitis
GR3034479T3 (en) Method of treating hyperproliferative vascular disease using rapamycin, eventually in combination with mycophenolic acid.
TW224051B (de)
FR2711957B1 (fr) Procédé et dispositif d'assemblage pour pièces de carrosserie.
DK0484281T3 (de)
EP0783378A4 (de) Behandlung von nylon und anderen textilien
AU1791895A (en) Method of preventing hyperproliferative vascular disease
TW275584B (de)
FR2714629B1 (fr) Procédé et dispositif d'ébavurage de pièces mécaniques.
GR3020310T3 (en) 29-Demethoxyrapamycin for inducing immunosuppression
GR3020383T3 (en) 1-Aryl-3-(3,4-dihydro-4-oxo-3-quinazolinyl)-urea fungicidal agents
EP0661401A3 (de) Textilmaterialienbehandlungsmittel.
EP0653208A3 (de) Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0729360A4 (de) Die behandlung oder vorbeugung der crohn'schen krankheit und/oder der ulzerativen kolitis
EP0610669A3 (de) Vorrichtung zum Behandeln von Körperteilen mit Vibrationen.
ZA932799B (en) Device for treating textile articles.
FR2682310B1 (fr) Pince de traction autoserrante pour le redressement d'elements de carrosserie deformes.
PH31412A (en) Method of treating septic shock using thymosin-alpha 1.
ITRM910449A1 (it) Procedimento per conformare e/o proteggere l'interno di un corpo cavo, e mezzi per la realizzazione di detto procedimento
GB9416000D0 (en) Textile treatment